uniQure Announces Pricing of its Public Offering
October 24 2017 - 8:14PM
YASTEST
LEXINGTON, Mass. and AMSTERDAM, the
Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) -- uniQure
N.V. (NASDAQ:QURE), a leading gene therapy company advancing
transformative therapies for patients with severe unmet medical
needs, such as hemophilia B, Huntington's disease and congestive
heart failure, today announced the pricing of its underwritten
public offering of 5,000,000 of its ordinary shares at a public
offering price of $18.25 per share. The gross proceeds to uniQure
from the offering, before deducting the underwriting discounts and
commissions and estimated offering expenses payable by uniQure, are
expected to be $91,250,000. All ordinary shares to be sold in the
offering are being sold by uniQure. In addition, uniQure has
granted to the underwriters a 30-day option to purchase up to
750,000 additional ordinary shares at the public offering price,
less underwriting discounts and commissions. The offering is
expected to close on or about October 27, 2017, subject to the
satisfaction of customary closing conditions.
Leerink Partners and Evercore ISI are
acting as joint book-running managers for the offering. Chardan is
acting as lead manager and H.C. Wainwright & Co. is acting as
co-manager for the offering.
The securities described above are
being offered by uniQure pursuant to its shelf registration
statement on Form S-3 (File No. 333-216701) filed with the
Securities Exchange Commission (the "SEC") on March 15, 2017, as
amended on May 15, 2017 and declared effective by the SEC on May
26, 2017. A preliminary prospectus supplement and accompanying
prospectus relating to the offering was filed with the SEC and a
final prospectus supplement and the accompanying prospectus
relating to this offering will be filed with the SEC. When
available, copies of the final prospectus supplement and the
accompanying prospectus relating to the offering may be obtained
from Leerink Partners LLC, Attention: Syndicate Department, One
Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800)
808-7525 ext. 6132 or by email at Syndicate@Leerink.com; and
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East
52nd Street, 36th Floor, New York, NY 10055, or by telephone at
(888) 474-0200, or by email at ecm.prospectus@evercore.com. The
preliminary prospectus supplement and accompanying prospectus is
also available, and the final prospectus supplement and
accompanying prospectus will be available, for free on the SEC's
website at http://www.sec.gov.
This press release shall not
constitute an offer to sell or the solicitation of an offer to buy
these securities, nor shall there be any sale of these securities,
in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction. Any offer, if at all, will be made only by means of
the prospectus supplement and accompanying prospectus forming a
part of the effective registration statement.
About
uniQure
uniQure is delivering on the promise
of gene therapy - single treatments with potentially curative
results. We are leveraging our modular and validated gene therapy
technology platform to advance a pipeline of proprietary and
partnered gene therapies to treat patients with hemophilia,
Huntington's disease and cardiovascular diseases.
Forward-Looking
Statement
This press release
contains certain statements that are forward-looking within the
meaning of Section 27a of the Securities Act of 1933, as amended,
and that involve risks and uncertainties. These statements include,
without limitation, statements regarding our expectations of market
conditions, the satisfaction of customary closing conditions
related to the public offering, and other statements including the
words "may," "will," "intend," and similar expressions (as well as
other words or expressions referencing future events, conditions or
circumstances), which constitute and are intended to identify
forward-looking statements. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors, including: the uncertainties related
to market conditions and the completion of the public offering on
the anticipated terms, or at all, continued interest in our rare
disease portfolio, the ability to develop our product candidates
and technologies, the impact of changes in the financial markets
and global economic conditions, and other risks as are set forth in
uniQure's Annual Report on Form 10-K and other reports filed by
uniQure with the SEC. uniQure undertakes no obligations to make any
revisions to the forward-looking statements contained in this
release or to update them to reflect events or circumstances
occurring after the date of this release, whether as a result of
new information, future developments or otherwise.
uniQure
Contacts
For
Investors:
Maria
Cantor
Direct : +339-970-7536
Mobile: 617-680-9452
m.cantor@uniQure.com
Eva M.
Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 70
e.mulder@uniQure.com
For
Media:
Tom
Malone
Direct: 339-970-7758
Mobile: 339-223-8541
t.malone@uniqure.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: uniQure N.V. via Globenewswire
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Mar 2024 to Apr 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2023 to Apr 2024